Pilot drug trial seeks to slow Muscle-Wasting disease
NCT ID NCT04004000
Summary
This study tested an oral drug called losmapimod in adults with FSHD1, a genetic muscle-wasting disease. The main goal was to check the drug's safety and see if it reached and affected the muscles over about a year of treatment. Researchers measured drug levels and specific proteins in the blood and muscle tissue from biopsies to understand how the drug worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboud University Medical Center
Nijmegen, 9101, Netherlands
Conditions
Explore the condition pages connected to this study.